Pathophysiological mechanism of non-HIV Pneumocystis jirovecii pneumonia

Respir Investig. 2022 Jul;60(4):522-530. doi: 10.1016/j.resinv.2022.04.002. Epub 2022 Apr 29.

Abstract

While Pneumocystis jirovecii pneumonia (PCP) can occur in immunocompromised patients with HIV infection, the prognosis of non-HIV PCP is still poor, showing a high mortality rate of 30%-75%. The pathophysiological mechanism of non-HIV PCP is quite different from that of HIV-PCP. Aging, underlying disease, dysbiotic gut microbiome, and Th1 predominance, leads to macrophagic polarization shifting from M2 to M1. These cause dysregulation in the host immunity against P. jirovecii, resulting in severe lung injury and a high mortality rate among non-HIV PCP patients. This review describes poor prognostic factors, an issue of predictive values used for general pneumonia practice, and new aspects, including the dysbiosis of the gut microbiome and macrophagic polarization in the treatment of non-HIV PCP.

Keywords: Human immunodeficiency virus; Macrophage polarization; Microbiome; Pneumocystis jirovecii pneumonia; Th1-predominance.

Publication types

  • Review

MeSH terms

  • HIV Infections* / complications
  • Humans
  • Immunocompromised Host
  • Pneumocystis carinii*
  • Pneumonia, Pneumocystis*
  • Prognosis